



Published in final edited form as:

J Pediatr Gastroenterol Nutr. 2019 November ; 69(5): 570–574. doi:10.1097/MPG.0000000000002426.

Depression Predicts Prolonged Length of Hospital Stay in Pediatric Inflammatory Bowel Disease

Perseus V. Patel, Matthew S. Pantell, Melvin B. Heyman, Sofia Verstraete

Department of Pediatrics, University of California San Francisco Benioff Children's Hospital San Francisco, CA

Abstract

Objective—Few studies report the impact of depression on inflammatory bowel disease (IBD)-related hospitalizations. We evaluated the association between depression and pediatric IBD-related hospitalizations. Our primary aim was to test the hypothesis that depression is associated with hospital length of stay (LOS); our secondary goal was to evaluate if patients with depression are at higher risk for undergoing additional imaging and procedures.

Methods—Data were extracted from the 2012 Kids Inpatient Database (KID), the largest nationally representative publicly available all-payer pediatric inpatient cross-sectional database in the United States. Hospitalizations for patients less than 21 years with a primary diagnosis Crohn disease (CD) or ulcerative colitis (UC) by *ICD-9* code were included. Multivariable logistic regression was used to predict long LOS controlling for patient- and hospital-level variables and for potential disease confounders.

Results—For primary IBD-related hospitalizations (N = 8222), depression was associated with prolonged LOS (odds ratio [OR] 1.50; 95% confidence interval [CI] 1.19–1.90) and total parenteral nutrition use (OR 1.54; 95% CI 1.04–2.27). Depression was not associated with increased likelihood of surgery (OR 0.97; 95% CI 0.72–1.30), endoscopy (OR 0.91; 95% CI 0.74–1.14), blood transfusion (OR 0.85; 95% CI 0.58–1.23), or abdominal imaging (OR 1.15; 95% CI 0.53–2.53).

Conclusions—Depression is associated with prolonged LOS in pediatric patients with IBD, even when controlling for gastrointestinal disease severity. Future research evaluating the efficacy of standardized depression screening and early intervention may be beneficial to improving inpatient outcomes in this population.

Keywords

Crohn disease; inpatient; mental health; parenteral nutrition; ulcerative colitis

Address correspondence and reprint requests to Perseus V. Patel, Department of Pediatrics, University of California San Francisco Benioff Children's Hospital San Francisco, 550 16th Street, 4th Floor, Box 0136, San Francisco, CA 94158 (perseus.patel@ucsf.edu).

The authors report no conflicts of interest

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jpagn.org).

M.B.H. is an Editor-in-Chief (NA) of the *Journal of Pediatric Gastroenterology and Nutrition*.

The psychosocial sequelae of inflammatory bowel disease (IBD) leave pediatric patients at increased risk for depression compared with healthy population controls and other children with chronic diseases (1–3). Burke et al (4) in 1989 reported that pediatric IBD patients have a higher lifetime risk of depression than pediatric cystic fibrosis patients. Although it is difficult to determine a precise prevalence of depression in pediatric IBD patients because of sample size limitations in pediatric research, rates range from 10% to 25% in studies larger than 20 patients (5). Depression in IBD populations is associated with poor quality of life, medication nonadherence, worsened abdominal pain, and increased risk of surgery and disease relapse (3). Researchers have also noted associations with increased disease activity, steroid prescriptions, flare frequency, suicide rates, and radiation exposure (6–9).

Despite the growing rate of pediatric IBD admissions, little information exists on the effects of depression on inpatient outcomes (10). A retrospective review of over 2700 pediatric IBD-related hospitalizations showed that depression was associated with an increased rate of readmission in pediatric patients with Crohn disease (CD) (11). A similar adult study documented an association of depression with readmission rate in both CD and ulcerative colitis (UC) (12). To build on the current literature, we evaluated the impact of depression on length of stay (LOS) for IBD-related admissions using a nationally representative pediatric sample. Secondary goals include investigating the association of depression on radiologic studies, blood transfusions, endoscopic and surgical procedures, and use of total parenteral nutrition (TPN).

METHODS

Database

We conducted a retrospective cross-sectional review utilizing the 2012 Kids' Inpatient Database (KID), the largest nationally representative pediatric (under 21 years of age) inpatient database in the United States (13). KID is a component of the Healthcare Cost and Utilization Project (HCUP), created by the Agency for Healthcare Research and Quality. The database extracts information from administrative discharge abstracts and includes de-identified patient data (diagnoses, procedures, demographics, insurance type, and total charges) and institutional data (hospital size, ownership, location, and teaching status) from 4179 hospitals across 44 states (13). KID implements a systematic randomized sampling methodology to collect its cohort and subsequently applies a discharge-weighting algorithm to generate a nationally representative sample. Additional details regarding the sampling and weighing protocols can be accessed through HCUP (14). Diagnoses and procedures are documented through International Classification of Diseases, Ninth Revision, Clinical Modification (*ICD-9-CM*) codes. Up to 25 diagnoses (DX1-DX25) and 15 procedure codes (PR1-PR15) can be entered for each hospitalization, with the first entry (DX1) being the primary diagnosis.

Study Population

Our study sample included all hospitalizations in which DX1, the primary reason for admission (14), involved a previously validated *ICD-9-CM* code for UC (*ICD-9: 556.x*) or CD (*ICD-9: 555.x*) (14,15). The sample was divided into hospitalizations that included a

nonprimary *ICD-9* coded diagnosis (DX2–DX25) of depression versus those that did not. Given the lack of standardized methodology, we opted for this conservative approach to ensure that the reason for hospitalization was related to IBD and not depression (10,11,16,17). We discovered 88 hospitalization records that included diagnoses of both UC and CD; however, as the subtype of IBD was not relevant to our study, these records were included in our final analyses. *ICD-9* codes for depression were extracted from a previous validation study (18). To ensure an accurate estimation of LOS, we excluded hospitalizations that involved a transfer to or from another institution and hospital stays that ended in a patient's death (19).

Data Analysis

The primary outcome of interest was length of hospital stay. Secondary outcomes included assessing rates of: TPN use, abdominal surgeries, endoscopic procedures, blood transfusions, cost, and abdominal imaging. A prolonged LOS was defined as >75th percentile of IBD hospitalizations, a standard used in previous literature (20). The predictor was an *ICD-9*-coded diagnosis of depression (18). For abdominal imaging, we evaluated X-rays and computerized tomography (CT) scans because of lack of specificity in *ICD-9* coding for other abdominal imaging modalities. Logistic regression was used to predict each outcome by depression.

We controlled for patient-level, hospital-level, and disease-specific confounders identified previously (10,11,16,19). Patient-specific confounders included: age, sex, race, median household income quartile of the zip code in which the patient lives, and type of insurance. Age groups were categorized based on the Paris Classification (21). Hospital-specific confounders included: bed size, geographic location, teaching status, hospital ownership, and annual volume of IBD admissions. Previous studies defined high-volume centers as those with over 20 pediatric IBD-related hospitalizations per year (10). IBD-related controls included: stricturing (B2), penetrating (B3), or perianal disease (p) as per the Paris Classification (21); extraintestinal disease; serious bacterial infections; malnutrition; anemia; and presence of an existing stoma. To control for potential confounding comorbidities, we controlled for number of chronic diseases, functional status, and the All Patient Refined Diagnosis Related Groups (APR-DRGs) mortality risk using pre-existing variables in the KID database. We adjusted for IBD-related controls based on content expertise and previous literature. We extracted all confounder and outcome *ICD-9* codes from previous studies (10,15,22,23). Chi-squared testing was used to compare the sociodemographic and health characteristics between hospitalizations with depression and those without (Supplemental Table 1, Supplemental Digital Content, <http://links.lww.com/MPG/B672>). See Supplemental Table 2 (Supplemental Digital Content, <http://links.lww.com/MPG/B672>) for detailed *ICD-9* codes.

Although a detailed cost analysis is beyond the scope of this article, we did estimate costs of inpatient care using unweighted total hospital charges from the KID database and multiplying by the KID's cost-to-charge ratio as per previous literature (24). In line with prior studies (19), all other analyses were performed on the survey-weighted hospitalizations using Stata SE 15.1 (StataCorp, College Station, TX). For regression analysis, a *P* level

<0.05 was considered to be significant. The study was classified as nonhuman subject research by the University of California, San Francisco Committee on Human Research and was, therefore, exempt from the Institutional Review Board.

RESULTS

The characteristics of pediatric IBD-related hospitalizations are outlined in Supplemental Table 1 (Supplemental Digital Content, <http://links.lww.com/MPG/B672>). There were 8222 unweighted IBD hospitalizations, which increased to 10,499 hospital stays after weighting. For hospitalizations involving IBD with comorbid depression, the median age was 17 years with an interquartile range (IQR) between 15 and 19 years. The majority of hospitalizations were female (53%), white (68.4%), and had a median household income in the fourth quartile (35.0%). The payment source for 60% of the hospital stays was private insurance. The majority of hospitalizations took place at private nonprofit (85.7%), urban teaching hospitals (79.1%) that had a large number of beds (70.2%). Hospital bed size was classified by the KID based upon the location and teaching status of the hospital (13). Geographically, 21.2% of hospitalizations were in the northeast, 24.7% in the midwest, 22% in the west, and 32.1% in the south. The majority of hospitalizations involved 2 to 4 chronic conditions (70.2%), and patients were mostly classified as having moderate loss of function (46.8%) with a minor risk of mortality (82.1%) during the hospitalization. IBD phenotype was reported as B2 in 10.7% of patients, and B3 in 3.3%. We were unable to report B2B3 as the number of hospitalizations was below the minimum required by HCUP (25). Perianal disease (p) was reported in 4.7%. A pre-existing ostomy was involved in 3.1% of hospitalizations. Comorbid complications of hospitalizations included a serious bacterial infection in 2.7%, anemia in 42.5%, and malnutrition in 19.4% (Supplemental Table 1, Supplemental Digital Content, <http://links.lww.com/MPG/B672>).

For hospitalizations involving IBD without comorbid depression, the median age was 16 years (IQR: 13–19 years). The majority of hospitalizations were boys (53.5%), white (61.9%), and had a median household income in the fourth quartile (33.3%). The payment source for most of the hospital stays was private insurance (64.8%). The majority of hospitalizations took place at private nonprofit (82.7%), urban teaching hospitals (78.4%) with a large number of beds (69.4%). Geographically, 23.7% of hospitalizations were in the northeast, 24.9% in the midwest, 18.2% in the west, and 33.1% in the south. Approximately half of the hospitalizations involved 2–4 chronic conditions (51.9%), and patients were mostly classified as having moderate loss of function (47.0%) with a minor risk of mortality (89.1%) during the hospitalization. IBD phenotype was reported as B2 in a smaller percentage (6.9%) but a significantly larger percentage (4.6%) had B3 ($P<0.01$). Perianal disease was reported in 3.9% of hospitalizations. A pre-existing ostomy was involved in 2.0% of hospitalizations. Comorbid complications of hospitalizations included a serious bacterial infection in 1.9%, anemia in 34.9%, and malnutrition in 13.7%. On the basis of chi-squared testing, patients with depression were more likely to have stricturing disease ($P<0.01$), anemia ($P<0.01$), malnutrition, ($P<0.01$) and more severe loss of function ($P<0.01$), and mortality risks ($P<0.01$; Supplemental Table 1, Supplemental Digital Content, <http://links.lww.com/MPG/B672>). We controlled for these differences in health characteristics in our logistic regression models.

In our sample of pediatric IBD-related hospitalizations, depression was associated with a prolonged LOS (odds ratio [OR] 1.50; 95% confidence interval [CI] 1.19–1.90). In our depression sample, the unweighted LOS was 5.0 ± 7.4 (median \pm SD) days, whereas the IBD-only cohort had a LOS of 4.0 ± 5.0 days.

Depression was also associated with increased odds of using TPN (OR 1.54; 95% CI 1.04–2.27). However, depression was not associated with increased likelihood of surgery (OR 0.97; 95% CI 0.72–1.30), endoscopic procedures (OR 0.91; 95% CI 0.74–1.14), abdominal imaging (OR 1.15; 95% CI 0.53–2.53), or blood transfusion (OR 0.85; 95% CI 0.58–1.23; Table 1).

Unweighted total hospital charges for IBD admissions involving depression (median = \$11,284.50; interquartile range [IQR] \$5,720.95–\$21,622.20) were higher than those that did not involve depression (median = \$8,460.81; IQR \$4,894.72–\$15,055.30). We are, however, unable to deduce statistical significance from these charges as a formal cost analysis was outside of the scope of this study.

DISCUSSION

Our study is one of the first to evaluate the association between depression and pediatric IBD-related hospitalization LOS. Using KID, we found that depression is associated with prolonged LOS and increased risk of initiating TPN during a hospitalization.

The strong association between depression and prolonged LOS remains despite controlling for multiple confounders. However, the cross sectional study design does not permit establishing causality. We hypothesize that overlap between the psychological and gastrointestinal diseases intensifies symptoms and induces diagnostic uncertainty that may warrant longer in-hospital monitoring. For example, depression can amplify visceral hypersensitization, and psychosocial dysfunction is known to magnify abdominal pain severity in adult IBD populations (2,3). Depression may also augment disease flares through suppression of anti-inflammatory mechanisms, thereby prolonging LOS. Inducing depression in animal models with quiescent colitis is reported to stimulate inflammatory cascades via impaired inhibition of proinflammatory cytokines by macrophages (26). Conversely, pediatric patients hospitalized for chronic medical conditions are more likely to develop depression than those admitted for an acute process (27). A study involving adolescent oncology patients revealed that disruptions in social development and roles were risk factors for developing depression, whereas meaningful relationships were deemed protective (28). We posit that these factors translate to our population. Depression with IBD is associated with missed school days, poor medication adherence, worsened fatigue, increased disease activity, and interpersonal difficulties (3,29–32). Therefore, as a result of prolonged hospitalizations that disrupt normal childhood, patients may lose some of these protective factors and be at higher risk of developing depression. The increased likelihood of starting TPN may also contribute to longer stays. This association remains statistically significant despite controlling for malnutrition, anemia, and severity of underlying gastrointestinal disease.

Historically, TPN has been used to treat severe IBD, especially in malnourished patients; however, recent pediatric guidelines suggest restricting its use to situations where enteral nutrition is insufficient to meet metabolic demand or in a pre-operative setting for an elective procedure (23). Depression in patients with IBD patients may exacerbate perceptions of disease severity and lead to earlier initiation of TPN. TPN is associated with increased cost, risk of central line infections, sepsis, deep venous thrombosis, and pulmonary embolism, and is not indicated to induce remission (23). Conversely, in pediatric CD, enteral therapy provides similar remission rates to corticosteroids (33). Our data show an association of depression with TPN use, but not with surgical or endoscopic procedures, which indicates that TPN use was likely extending beyond periprocedural time points. Previous data have highlighted barriers to adoption of new guidelines in other disease states, and we hypothesize that similar obstacles may contribute to increased TPN use in depressed patients (34,35). Pediatric gastroenterology consortia, as well as individual providers, may need to assume additional responsibility to disseminate and implement society guidelines to address disparities in care.

Similar to other trials utilizing the KID database, our study is limited by the use of *ICD-9* codes, which are specific but not sensitive for detecting conditions (36,37). *ICD-9* coding may vary between providers, which poses difficulties in standardizing our cohort. Depression is under-diagnosed in IBD populations (38), which presents a challenge in categorizing our study groups. Patients in the IBD-only cohort may have undiagnosed depression, or a depression diagnosis given in an outpatient clinic may not have transferred into the hospitalization chart. Additionally, as KID is a hospitalization-level database, a single patient may account for multiple hospitalizations. KID does not include patient-level disease-specific clinical data, which makes it difficult to comprehensively control for gastrointestinal disease severity. In addition, despite our controls, it is possible that conditions for which we did not control may influence LOS. Similarly, a patient admitted for a primary IBD-related diagnosis may subsequently require additional inpatient time to better stabilize their mental health. Given the variability in access to mental health services across hospital systems, this many contribute to increased LOS. Future research involving the severity and duration of each patient's depression, possible effects of depression on other measures of severity and mortality, and the types of treatment applied to each is needed to further elucidate the impact of mental health disorders on hospital and patient outcomes.

Our study found that depression is associated with prolonged LOS and increased TPN use in pediatric IBD-related hospitalizations using a nationally representative cohort. Further research will better characterize these correlations and can explore potential methods to mitigate discrepancies in care. An evaluation of differences in outcomes between high-volume and low-volume IBD centers can assess if IBD-specific expertise can minimize divergent outcomes in patients with depression. Present data using high-volume IBD centers showcase improved surgical outcomes and remission rates (39,40). We hypothesize that similar benefits may be seen in LOS and TPN use. Longitudinal and prospective studies are required to further elucidate the issue of causality.

A growing base of research highlights the benefits of intervention involving outpatient psychiatric care. A randomized control trial that examined the effect of 3 months of

psychotherapy on children with IBD and depression found that therapy helped reduce hospitalizations, emergency department visits, endoscopic procedures, and radiologic studies (3). Both supportive therapy and cognitive behavioral therapy (CBT) improve depressive symptoms and psychosocial functioning in pediatric IBD patients, with CBT also correlated with decreased IBD activity (2,41–43). Our study findings advocate for increased access to mental health care to investigate the effects on LOS and TPN use. Given the previously cited data, we hypothesize that outpatient interventions will reveal similarly beneficial effects.

Another avenue for future research is the development of a transitional care plan to potentially decrease LOS. Prospective trials are needed to evaluate if close postdischarge gastroenterology follow-up can facilitate an earlier discharge by allowing treatment delivery or monitoring in an outpatient setting. Care coordination models with structured postdischarge transitions plans can be effective at reducing hospital stays and costs in medically complex adult patients (44).

Annual IBD-related expenses in the United States amount to approximately \$6.3 billion, with approximately 30 to 40% of the cost attributed to hospital care (3,45). Hospitalization research on other diseases, such as bronchiolitis has shown that differences in LOS of less than a single day are strongly associated with decreased healthcare expenditure (46). Our initial cost statistics suggest that IBD admissions involving depression are more expensive, but additional cost analyses are needed to validate the statistical significance of these findings.

CONCLUSIONS

In summary, our retrospective database review of a nationally representative sample reveals that depression in pediatric IBD-related hospitalizations is associated with prolonged LOS and increased risk of initiating TPN. Future research should evaluate the causality and examine the efficacy of outpatient interventions and transitional care models to optimize inpatient outcomes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

S.V. is a Watson Scholar supported by the UCSF Dean's Diversity Award.

REFERENCES

1. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. *JAMA Pediatr* 2015;169:1053–60. [PubMed: 26414706]
2. Keethy D, Mrakotsky C, Szigethy E. Pediatric inflammatory bowel disease and depression: treatment implications. *Curr Opin Pediatr* 2014;26:561–7. [PubMed: 25010217]
3. Keerthy D, Youk A, Srinath AI, et al. Effect of psychotherapy on health care utilization in children with inflammatory bowel disease and depression. *J Pediatr Gastroenterol Nutr* 2016;63:658–64. [PubMed: 27035372]

4. Burke P, Meyer V, Kocoshis S, et al. Depression and anxiety in pediatric inflammatory bowel disease and cystic fibrosis. *J Am Acad Child Adolesc Psychiatry* 1989;28:948–51. [PubMed: 2808268]
5. Greenley RN, Hommel KA, Nebel J, et al. A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease. *J Pediatr Psychol* 2010;35:857–69. [PubMed: 20123705]
6. Gradus JL, Qin P, Lincoln AK, et al. Inflammatory bowel disease and completed suicide in Danish adults. *Inflamm Bowel Dis* 2010;16: 2158–61. [PubMed: 20848460]
7. Panara AJ, Yarur AJ, Rieders B, et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. *Aliment Pharmacol Ther* 2014;39:802–10. [PubMed: 24588323]
8. Mikocka-Walus A, Pittet V, Rossel JB, et al., Swiss IBD Cohort Study Group. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2016;14:829.e1–35.e1. [PubMed: 26820402]
9. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. *Psychosom Med* 2004;66:79–84. [PubMed: 14747641]
10. Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. *Am J Gastroenterol* 2008;103:2789–98. [PubMed: 18684184]
11. Barnes EL, Kochar B, Long MD, et al. The burden of hospital readmissions among pediatric patients with inflammatory bowel disease. *J Pediatr* 2017;191:184.e1–9.e1. [PubMed: 29037795]
12. Allegretti JR, Borges L, Lucci M, et al. Risk factors for rehospitalization within 90 days in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2015;21:2583–9. [PubMed: 26244647]
13. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). 9 2018 Agency for Healthcare Research and Quality, Rockville, MD Available at: www.hcup-us.ahrq.gov/kidoverview.jsp. Accessed November 27, 2018.
14. HCUP Databases. Introduction to the HCUP Kids' Inpatient Database. Available at: https://www.hcup-us.ahrq.gov/db/nation/kid/KID_2012_Introduction.pdf. Accessed February 19, 2019.
15. Thirumurthi S, Chowdhury R, Richardson P, et al. Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans. *Dig Dis Sci* 2010;55:2592–8. [PubMed: 20033847]
16. Barnes EL, Kochar B, Long MD, et al. Minority pediatric patients with inflammatory bowel disease demonstrate an increased length of stay. *Inflamm Bowel Dis* 2017;23:2189–96. [PubMed: 29140942]
17. Pant C, Deshpande A, Sferra TJ, et al. Pediatric hospitalizations for inflammatory bowel disease based on annual case volume: results from the Kids' Inpatient Database 2012. *J Investig Med* 2017;65:94–6.
18. Fiest KM, Jette N, Quan H, et al. Systematic review and assessment of validated case definitions for depression in administrative data. *BMC Psychiatry* 2014;14:289. [PubMed: 25322690]
19. Kaiser SV, Bakel LA, Okumura MJ, et al. Risk factors for prolonged length of stay or complications during pediatric respiratory hospitalizations. *Hosp Pediatr* 2015;5:461–73. [PubMed: 26330245]
20. McKenna NP, Potter DD, Bews KA, et al. Ileal-pouch anal anastomosis in pediatric NSQIP: does a laparoscopic approach reduce complications and length of stay? *J Pediatr Surg* 2019;54:112–7. [PubMed: 30482542]
21. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis* 2011;17:1314–21. [PubMed: 21560194]
22. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. *Clin Gastroenterol Hepatol* 2007;5:597–601. [PubMed: 17382602]
23. Ananthakrishnan AN, Gainer VS, Perez RG, et al. Psychiatric comorbidity is associated with increased risk of surgery in Crohn's disease. *Aliment Pharmacol Ther* 2013;37:445–54. [PubMed: 23289600]
24. Raol N, Zogg CK, Boss EF, et al. Inpatient pediatric tonsillectomy: does hospital type affect cost and outcomes of care? *Otolaryngol Head Neck Surg* 2016;154:486–93. [PubMed: 26701174]

25. DUA Training - Accessible Version. Healthcare Cost and Utilization Project (HCUP). 9 2017 Agency for Healthcare Research and Quality, Rockville, MD Available at: www.hcup-us.ahrq.gov/DUA/dua_508/DUA508version.jsp. Accessed March 12, 2019.
26. Ghia JE, Blennerhassett P, Deng Y, et al. Reactivation of inflammatory bowel disease in a mouse model of depression. *Gastroenterology* 2009;136:2280.e1–8e. [PubMed: 19272381]
27. Esmaeeli MR, Erfani Sayar R, Saghebi A, et al. Screening for depression in hospitalized pediatric patients. *Iran J Child Neurol* 2014;8:47–51. [PubMed: 24665327]
28. Park EM, Rosenstein DL. Depression in adolescents and young adults with cancer. *Dialogues Clin Neurosci* 2015;17:171–80. [PubMed: 26246791]
29. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. *J Pediatr Psychol* 2008;33:867–74. [PubMed: 18337262]
30. Hommel KA, Davis CM, Baldassano RN Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. *Inflamm Bowel Dis* 2009;15:589–93. [PubMed: 18985746]
31. Mackner LM, Crandall WV. Long-term psychosocial outcomes reported by children and adolescents with inflammatory bowel disease. *Am J Gastroenterol* 2005;100:1386–92. [PubMed: 15929775]
32. Mackner LM, Crandall WV, Szigethy EM. Psychosocial functioning in pediatric inflammatory bowel disease. *Inflamm Bowel Dis* 2006;12:239–44. [PubMed: 16534426]
33. Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: the established and the new. *World J Gastroenterol* 2016;22:2179–94. [PubMed: 26900283]
34. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. *JAMA* 1999;282:1458–65. [PubMed: 10535437]
35. Mickan S, Burls A, Glasziou P. Patterns of 'leakage' in the utilisation of clinical guidelines: a systematic review. *Postgrad Med J* 2011;87:670–9. [PubMed: 21715571]
36. Patrick SW, Davis MM, Sedman AB, et al. Accuracy of hospital administrative data in reporting central line-associated bloodstream infections in newborns. *Pediatrics* 2013;131(Suppl 1): S75–80. [PubMed: 23457153]
37. Aronson PL, Williams DJ, Thurm C, et al., Febrile Young Infant Research Collaborative. Accuracy of diagnosis codes to identify febrile young infants using administrative data. *J Hosp Med* 2015;10:787–93. [PubMed: 26248691]
38. Lewis K, Marrie RA, Bernstein CN, et al., CIHR Team in Defining the Burden and Managing the Effects of Immune-Mediated Inflammatory Disease. The prevalence and risk factors of undiagnosed depression and anxiety disorders among patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2019[Epub ahead of print].
39. Shah R, Hou JK. Approaches to improve quality of care in inflammatory bowel diseases. *World J Gastroenterol* 2014;20:9281–5. [PubMed: 25071321]
40. Law CC, Sasidharan S, Rodrigues R, et al. Impact of specialized inpatient IBD care on outcomes of IBD hospitalizations: a cohort study. *Inflamm Bowel Dis* 2016;22:2149–57. [PubMed: 27482978]
41. Szigethy E, Whitton SW, Levy-Warren A, et al. Cognitive-behavioral therapy for depression in adolescents with inflammatory bowel disease: a pilot study. *J Am Acad Child Adolesc Psychiatry* 2004;43:1469–77. [PubMed: 15564816]
42. Thompson RD, Craig A, Crawford EA, et al. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. *J Clin Psychol Med Settings* 2012;19: 329–37. [PubMed: 22699797]
43. Szigethy E, Bujoreanu SI, Youk AO, et al. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. *J Am Acad Child Adolesc Psychiatry* 2014;53:726–35. [PubMed: 24954822]
44. Berry LL, Rock BL, Smith Houskamp B, et al. Care coordination for patients with complex health profiles in inpatient and outpatient settings. *Mayo Clin Proc* 2013;88:184–94. [PubMed: 23290738]

45. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. *Gastroenterology* 2008;135:1907–13. [PubMed: 18854185]
46. Bryan MA, Desai AD, Wilson L, et al. Association of bronchiolitis clinical pathway adherence with length of stay and costs. *Pediatrics* 2017;139:pii: e20163432. [PubMed: 28183732]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

What Is Known

- Pediatric inflammatory bowel disease patients are at increased risk of depression.
- Depression in inflammatory bowel disease is associated with poor quality of life, medication nonadherence, worse abdominal pain, and increase risk of surgery, relapse, and readmission.

What Is New

- Depression correlates directly with increased length of stay in pediatric patients hospitalized for inflammatory bowel disease.
- Depression correlates directly with increased use of total parenteral nutrition.
- Depression does not correlate with an increased risk of blood transfusions, abdominal imaging, or the likelihood for endoscopic or surgical procedures in pediatric patients hospitalized for inflammatory bowel disease.

Table 1:

Association between depression and outcomes for pediatric inflammatory bowel disease (IBD)-related hospital stays

Outcome	All centers OR [95% CI]	All Centers P-value
Prolonged length of stay*	1.50 [1.19–1.90]	P<0.01
Total parenteral nutrition	1.54 [1.04–2.27]	P=0.03
Surgery	0.97 [0.72–1.30]	P=0.82
Endoscopy	0.91 [0.74–1.14]	P=0.43
Transfusion	0.85 [0.58–1.23]	P=0.38
Abdominal Imaging	1.15 [0.53–2.53]	P=0.72

Adjusted for demographics (age, gender, race, income quartile, insurance type), hospital-level variables (bed size, ownership, location, teaching status, GI disease (stricturing, penetrating, perianal disease, existing ostomy, malnutrition), comorbidities (number of chronic conditions, anemia, bacterial infection), functional status (pre-existing database variable), and mortality risk (pre-existing database variable).

* Defined as >75th percentile